PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
Checked against the public recordLast updated May 21, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-00299804; Drug: PF-00299804
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Advanced Non-Small Cell Lung Cancer (NSCLC) * Prior treatment with and failure of at least one regimen of chemotherapy and erlotinib. * Prior treatment with no more than two chemotherapy regimens, including adjuvant or combined modality treatment. * Measurable disease . * Eastern Cooperative Oncology Group (ECOG) Performance status 0-2 * Tissue available for KRAS/ EGFR testing * Creatinine clearance \> 40 cc/min or serum creat \< 1.5 x ULN Exclusion Criteria: * Chemotherapy * Radiotherapy * Biological or investigational agents within 4 weeks of baseline disease assessment. * Patients who lack of tolerance of erlotinib therapy.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- City of HopeDuarte, California
- City of Hope Medical GroupPasadena, California
- City of Hope South Pasadena Cancer CenterSouth Pasadena, California
- Rocky Mountain Lions Eye InstituteAurora, Colorado
- University of Colorado Hospital, Anschutz Cancer PavilionAurora, Colorado
- University of Colorado Hospital, Anschutz Inpatient PavilionAurora, Colorado
- University of Colorado HospitalAurora, Colorado
- Grady Health SystemsAtlanta, Georgia
- Emery University Hospital MidtownAtlanta, Georgia
- Emory ClinicAtlanta, Georgia
- Emory University HospitalAtlanta, Georgia
- Winship Cancer InstituteAtlanta, Georgia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 21, 2019. Always confirm current availability with the study team.